BioCentury
ARTICLE | Clinical News

COM completes enrollment in fibrillation Phase III

October 12, 2004 7:00 AM UTC

Cardiome (TSE:COM; CRME) completed enrollment of 420 patients with atrial fibrillation in the Phase III ACT-1 trial of its RSD1235 antiarrhythmic. The primary endpoint is acute conversion to normal he...